Recent Finacing
Recent Raise
Adaptate develops monoclonal and bispecific antibodies targeting gamma-delta T cells to treat solid tumors, progressing lead programs toward clinical trials while expanding R&D and laboratory capabilities.
Focus Areas
Recent Investors
Funding round
Investors
See the team members at Adaptate Biotherapeutics.
